Novoprotein: Its high-throughput wet-lab and data package services that empower AI are still in the early stage of market expansion, with related revenue accounting for less than 2%
English text is being prepared.
Novoprotein announced that its high-throughput wet-lab and data package services that empower AI are still in the early stage of market expansion, and as of the third quarter of 2026, revenue from related businesses accounted for less than 2% of the company's total operating revenue. The company cautioned that the application of AI in the drug R&D industry is still in its infancy, and there are risks such as rapid technological iteration, long industry validation cycles, and significant difficulty in commercial implementation, and future realization of related revenue and profits is subject to major uncertainty. Previously, the company's stock price rose by a cumulative deviation of more than 30% over three consecutive trading days from October 28 to 30, constituting an abnormal fluctuation in stock trading.
Body
近岸蛋白公告称，公司股票于10月28日至30日连续3个交易日收盘价格涨幅偏离值累计超30%，属于股票交易异常波动。公司赋能AI的高通量湿实验与数据包服务尚处于市场拓展初期，截至2026年第三季度相关业务营收占公司整体营业收入比重不足2%。鉴于AI在药物研发行业的应用尚处于起步阶段，存在技术迭代较快、行业验证周期长、商业化落地难度较大等风险，公司未来相关收入及盈利兑现存在重大不确定性，提请广大投资者理性看待，注意投资风险。